QuellTX
Helen Lock, PhD has a diverse work experience spanning both academia and pharmaceutical companies. Helen is currently a Principal Scientist at Quell Therapeutics, a position they started in December 2022. Prior to this, they held the role of Senior AD/QC Scientist at the same company from September 2020 to December 2022.
Before joining Quell Therapeutics, Helen worked at GSK for a significant period. Helen started as a Scientist in July 2000 and later became a Senior Scientist in August 2009. In October 2018, they transitioned to the role of Investigator and held it until September 2020.
Helen's academic experience includes a Postdoctoral Research Associate position at Cambridge University, where they worked from July 2006 to August 2009. Helen also completed their PhD at the University of Dundee from March 2003 to July 2006.
Earlier in their career, Helen worked as a Scientific Officer at Cancer Research UK from April 2001 to March 2003.
Overall, Helen Lock, PhD has a strong background in scientific research and has held various key positions in prestigious organizations throughout their career.
Helen Lock, PhD, completed their education with a focus on Immunology. Helen obtained their PhD from the University of Dundee, where they studied from 2003 to 2006. Prior to that, they pursued a Bachelor of Science degree in Cell and Molecular Biology from the University of Essex, graduating with a Class 2.i. Honours in 2000. Helen'searliest educational experience was at Maidstone Grammar School for Girls between 1993 and 1997; however, the specific degree obtained or field of study pursued during this time is not provided.
This person is not in the org chart
QuellTX
4 followers
Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions.Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cellengineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.